From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Last Updated: Tuesday, October 4, 2022

A phase 2 trial evaluated itacitinib, a selective JAK1 inhibitor, in 70 patients with low risk acute GvHD, versus 140 who were treated with standard-of-care high dose systemic corticosteroids. It found that itacitinib resulted in fewer serious infections compared to systemic corticosteroids. 

Blood
Advertisement
News & Literature Highlights
Advertisement
Advertisement